Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):40–49. doi: 10.1054/bjoc.2000.1280

Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma

C P F Taylor 1, N P Bown 2, A G McGuckin 3, J Lunec 3, A J Malcolm 4, A D J Pearson 5, D Sheer 1; on behalf of the United Kingdom Children's Cancer Study Group1
PMCID: PMC2374533  PMID: 10883666

Abstract

Neuroblastoma is the commonest extracranial solid tumour in children. There are a number of molecular genetic features known which are of prognostic importance and which are used to direct therapy. Identification and targeting of high-risk individuals with intensive therapeutic regimens may allow an improvement in survival rates. The most powerful biological parameters associated with prognosis in this malignancy are chromosomal changes, especially MYCN amplification, deletion of chromosome 1p and aneuploidy. Rapid characterization of these aberrations at the time of diagnosis is paramount if stratification according to risk group is to be achieved. This paper describes the rapid detection of del(1p), MYCN amplification and trisomy using interphase fluorescence in situ hybridization on imprints from fresh tumour biopsies. The results are related to those obtained by standard molecular methods and karyotyping. © 2000 Cancer Research Campaign

Keywords: prognosis, fluorescence in situ hybridization (FISH), MYCN, del(1p), ploidy

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambros P. F., Ambros I. M., Strehl S., Bauer S., Luegmayr A., Kovar H., Ladenstein R., Fink F. M., Horcher E., Printz G. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer. 1995;31A(4):510–515. doi: 10.1016/0959-8049(95)00044-j. [DOI] [PubMed] [Google Scholar]
  2. Avet-Loiseau H., Venuat A. M., Benard J., Leibovitch M. P., Hartmann O., Bernheim A. Morphologic and molecular cytogenetics in neuroblastoma. Cancer. 1995 Apr 1;75(7):1694–1699. doi: 10.1002/1097-0142(19950401)75:7<1694::aid-cncr2820750721>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Bourhis J., Dominici C., McDowell H., Raschella G., Wilson G., Castello M. A., Plouvier E., Lemerle J., Riou G., Bénard J. N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol. 1991 Aug;9(8):1371–1375. doi: 10.1200/JCO.1991.9.8.1371. [DOI] [PubMed] [Google Scholar]
  4. Bown N., Cotterill S., Lastowska M., O'Neill S., Pearson A. D., Plantaz D., Meddeb M., Danglot G., Brinkschmidt C., Christiansen H. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999 Jun 24;340(25):1954–1961. doi: 10.1056/NEJM199906243402504. [DOI] [PubMed] [Google Scholar]
  5. Brodeur G. M., Fong C. T. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet. 1989 Sep;41(2):153–174. doi: 10.1016/0165-4608(89)90243-4. [DOI] [PubMed] [Google Scholar]
  6. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  7. Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 8;224(4653):1121–1124. doi: 10.1126/science.6719137. [DOI] [PubMed] [Google Scholar]
  8. Caron H., van Sluis P., de Kraker J., Bökkerink J., Egeler M., Laureys G., Slater R., Westerveld A., Voûte P. A., Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):225–230. doi: 10.1056/NEJM199601253340404. [DOI] [PubMed] [Google Scholar]
  9. Caron H., van Sluis P., van Hoeve M., de Kraker J., Bras J., Slater R., Mannens M., Voûte P. A., Westerveld A., Versteeg R. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet. 1993 Jun;4(2):187–190. doi: 10.1038/ng0693-187. [DOI] [PubMed] [Google Scholar]
  10. Castleberry R. P., Pritchard J., Ambros P., Berthold F., Brodeur G. M., Castel V., Cohn S. L., De Bernardi B., Dicks-Mireaux C., Frappaz D. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997 Oct;33(12):2113–2116. doi: 10.1016/s0959-8049(97)00202-5. [DOI] [PubMed] [Google Scholar]
  11. Christiansen H., Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer. 1988 Jan;57(1):121–126. doi: 10.1038/bjc.1988.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Christiansen H., Schestag J., Christiansen N. M., Grzeschik K. H., Lampert F. Clinical impact of chromosome 1 aberrations in neuroblastoma: a metaphase and interphase cytogenetic study. Genes Chromosomes Cancer. 1992 Sep;5(2):141–149. doi: 10.1002/gcc.2870050208. [DOI] [PubMed] [Google Scholar]
  13. Combaret V., Turc-Carel C., Thiesse P., Rebillard A. C., Frappaz D., Haus O., Philip T., Favrot M. C. Sensitive detection of numerical and structural aberrations of chromosome 1 in neuroblastoma by interphase fluorescence in situ hybridization. Comparison with restriction fragment length polymorphism and conventional cytogenetic analyses. Int J Cancer. 1995 Apr 10;61(2):185–191. doi: 10.1002/ijc.2910610208. [DOI] [PubMed] [Google Scholar]
  14. Cooke H. J., Hindley J. Cloning of human satellite III DNA: different components are on different chromosomes. Nucleic Acids Res. 1979 Jul 25;6(10):3177–3197. doi: 10.1093/nar/6.10.3177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Crabbe D. C., Peters J., Seeger R. C. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol. 1992 Dec;1(4):229–234. [PubMed] [Google Scholar]
  16. Eckschlager T., McClain K. Comparison of fluorescent in situ hybridization (FISH) and the polymerase chain reaction (PCR) for detection of residual neuroblastoma cells. Neoplasma. 1996;43(5):301–303. [PubMed] [Google Scholar]
  17. Evans A. E., D'Angio G. J., Propert K., Anderson J., Hann H. W. Prognostic factor in neuroblastoma. Cancer. 1987 Jun 1;59(11):1853–1859. doi: 10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  18. Fong C. T., Dracopoli N. C., White P. S., Merrill P. T., Griffith R. C., Housman D. E., Brodeur G. M. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A. 1989 May;86(10):3753–3757. doi: 10.1073/pnas.86.10.3753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fong C. T., White P. S., Peterson K., Sapienza C., Cavenee W. K., Kern S. E., Vogelstein B., Cantor A. B., Look A. T., Brodeur G. M. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 1;52(7):1780–1785. [PubMed] [Google Scholar]
  20. Gansler T., Chatten J., Varello M., Bunin G. R., Atkinson B. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer. 1986 Dec 1;58(11):2453–2458. doi: 10.1002/1097-0142(19861201)58:11<2453::aid-cncr2820581117>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  21. Hayashi Y., Kanda N., Inaba T., Hanada R., Nagahara N., Muchi H., Yamamoto K. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer. 1989 Jan 1;63(1):126–132. doi: 10.1002/1097-0142(19890101)63:1<126::aid-cncr2820630120>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  22. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lastowska M., Nacheva E., McGuckin A., Curtis A., Grace C., Pearson A., Bown N. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromosomes Cancer. 1997 Mar;18(3):162–169. [PubMed] [Google Scholar]
  24. Look A. T., Hayes F. A., Nitschke R., McWilliams N. B., Green A. A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984 Jul 26;311(4):231–235. doi: 10.1056/NEJM198407263110405. [DOI] [PubMed] [Google Scholar]
  25. Look A. T., Hayes F. A., Shuster J. J., Douglass E. C., Castleberry R. P., Bowman L. C., Smith E. I., Brodeur G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581–591. doi: 10.1200/JCO.1991.9.4.581. [DOI] [PubMed] [Google Scholar]
  26. Meddeb M., Danglot G., Chudoba I., Vénuat A. M., Bénard J., Avet-Loiseau H., Vasseur B., Le Paslier D., Terrier-Lacombe M. J., Hartmann O. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer. 1996 Nov;17(3):156–165. doi: 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  27. Oppedal B. R., Storm-Mathisen I., Lie S. O., Brandtzaeg P. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer. 1988 Aug 15;62(4):772–780. doi: 10.1002/1097-0142(19880815)62:4<772::aid-cncr2820620422>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  28. Peter M., Michon J., Vielh P., Neuenschwander S., Nakamura Y., Sonsino E., Zucker J. M., Vergnaud G., Thomas G., Delattre O. PCR assay for chromosome 1p deletion in small neuroblastoma samples. Int J Cancer. 1992 Oct 21;52(4):544–548. doi: 10.1002/ijc.2910520408. [DOI] [PubMed] [Google Scholar]
  29. Pinkel D., Straume T., Gray J. W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci U S A. 1986 May;83(9):2934–2938. doi: 10.1073/pnas.83.9.2934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rubie H., Delattre O., Hartmann O., Combaret V., Michon J., Bénard J., Peyroulet M. C., Plantaz D., Coze C., Chastagner P. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). Eur J Cancer. 1997 Oct;33(12):1917–1922. doi: 10.1016/s0959-8049(97)00295-5. [DOI] [PubMed] [Google Scholar]
  31. Schleiermacher G., Peter M., Michon J., Hugot J. P., Vielh P., Zucker J. M., Magdelénat H., Thomas G., Delattre O. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer. 1994 Aug;10(4):275–281. doi: 10.1002/gcc.2870100409. [DOI] [PubMed] [Google Scholar]
  32. Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983 Sep 15;305(5931):245–248. doi: 10.1038/305245a0. [DOI] [PubMed] [Google Scholar]
  33. Schwab M., Varmus H. E., Bishop J. M., Grzeschik K. H., Naylor S. L., Sakaguchi A. Y., Brodeur G., Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 1984 Mar 15;308(5956):288–291. doi: 10.1038/308288a0. [DOI] [PubMed] [Google Scholar]
  34. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  35. Shapiro D. N., Valentine M. B., Rowe S. T., Sinclair A. E., Sublett J. E., Roberts W. M., Look A. T. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol. 1993 May;142(5):1339–1346. [PMC free article] [PubMed] [Google Scholar]
  36. Shimada H., Chatten J., Newton W. A., Jr, Sachs N., Hamoudi A. B., Chiba T., Marsden H. B., Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984 Aug;73(2):405–416. doi: 10.1093/jnci/73.2.405. [DOI] [PubMed] [Google Scholar]
  37. Stock C., Ambros I. M., Mann G., Gadner H., Amann G., Ambros P. F. Detection of Ip36 deletions in paraffin sections of neuroblastoma tissues. Genes Chromosomes Cancer. 1993 Jan;6(1):1–9. doi: 10.1002/gcc.2870060103. [DOI] [PubMed] [Google Scholar]
  38. Takayama H., Suzuki T., Mugishima H., Fujisawa T., Ookuni M., Schwab M., Gehring M., Nakamura Y., Sugimura T., Terada M. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992 Jun;7(6):1185–1189. [PubMed] [Google Scholar]
  39. Takeda O., Homma C., Maseki N., Sakurai M., Kanda N., Schwab M., Nakamura Y., Kaneko Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer. 1994 May;10(1):30–39. doi: 10.1002/gcc.2870100106. [DOI] [PubMed] [Google Scholar]
  40. Taylor C. P., McGuckin A. G., Bown N. P., Reid M. M., Malcolm A. J., Pearson A. D., Sheer D. Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridisation on tumour imprints and bone marrow smears. United Kingdom Children's Cancer Study Group. Br J Cancer. 1994 Mar;69(3):445–451. doi: 10.1038/bjc.1994.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Taylor S. R., Blatt J., Costantino J. P., Roederer M., Murphy R. F. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer. 1988 Aug 15;62(4):749–754. doi: 10.1002/1097-0142(19880815)62:4<749::aid-cncr2820620418>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  42. Taylor S. R., Locker J. A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer. 1990 Mar 15;65(6):1360–1366. doi: 10.1002/1097-0142(19900315)65:6<1360::aid-cncr2820650619>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  43. Tsuda T., Obara M., Hirano H., Gotoh S., Kubomura S., Higashi K., Kuroiwa A., Nakagawara A., Nagahara N., Shimizu K. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer. 1987 Aug 15;60(4):820–826. doi: 10.1002/1097-0142(19870815)60:4<820::aid-cncr2820600418>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  44. Weith A., Martinsson T., Cziepluch C., Brüderlein S., Amler L. C., Berthold F., Schwab M. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosomes Cancer. 1989 Nov;1(2):159–166. doi: 10.1002/gcc.2870010209. [DOI] [PubMed] [Google Scholar]
  45. White P. S., Kaufman B. A., Marshall H. N., Brodeur G. M. Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. Genes Chromosomes Cancer. 1993 Jun;7(2):102–108. doi: 10.1002/gcc.2870070207. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES